Understanding the diversity and adaptability of lung cancer cells
Lineage heterogeneity and plasticity in lung cancer
This study is looking at how different types of lung cancer cells behave and change, so we can find out which genetic traits make them more likely to respond to certain treatments, with the goal of creating better therapies to help patients live longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10703434 on NIH RePORTER |
What this research studies
This research investigates the complex nature of lung cancer by examining how different subtypes of cancer cells can vary and adapt, which affects treatment outcomes. The team aims to identify specific genetic features that contribute to this variability, focusing on how certain genes are amplified in some cancer cells, making them vulnerable to targeted therapies. By understanding these mechanisms, the research seeks to develop more effective treatment strategies that can improve patient survival rates. Patients may be involved in this research to help identify these genetic markers and test new therapeutic approaches.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with lung cancer, particularly those whose tumors exhibit genetic heterogeneity.
Not a fit: Patients with non-malignant lung conditions or those whose lung cancer does not exhibit genetic variability may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatments for lung cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting genetic vulnerabilities in cancer cells, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Watanabe, Hideo — Icahn School of Medicine at Mount Sinai
- Study coordinator: Watanabe, Hideo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.